Tolsma S S, Cohen J D, Ehrlich L S, Bouck N P
Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, Illinois 60611.
Exp Cell Res. 1993 Apr;205(2):232-9. doi: 10.1006/excr.1993.1081.
Despite their familiar sensitivity to transformation by dominant-acting ras oncogenes, NIH/3T3 cells carry a ras suppressor. When tested by cell fusion they were able to suppress the anchorage-independent phenotype of both mouse and human cells transformed by activated H-ras or N-ras. This suppression occurred without a decrease in expression of the activated ras oncogene. Ras-transformed NIH/3T3 clones cured of their oncogene by benzamide treatment reverted to a nontransformed phenotype, but had lost the ability to suppress other ras transformants, indicating that their initial transformation was accompanied by suppressor loss. In hamster cells an active ras oncogene increased the rate of chromosome segregation by > 100-fold. These results suggest that in vitro transformation of NIH/3T3 cells by ras may be more similar to multistep in vivo tumor development than previously suspected, involving not only expression of an active oncogene but also loss of a suppressor activity, perhaps induced by the clastogenic oncogene.
尽管NIH/3T3细胞对显性作用的ras癌基因转化具有常见的敏感性,但它们携带一种ras抑制因子。通过细胞融合测试时,它们能够抑制由活化的H-ras或N-ras转化的小鼠和人类细胞的不依赖贴壁生长表型。这种抑制发生时,活化的ras癌基因的表达并未降低。经苯甲酰胺处理治愈其癌基因的ras转化NIH/3T3克隆恢复为非转化表型,但失去了抑制其他ras转化细胞的能力,这表明它们最初的转化伴随着抑制因子的丧失。在仓鼠细胞中,一个活性ras癌基因使染色体分离速率增加了100倍以上。这些结果表明,ras对NIH/3T3细胞的体外转化可能比以前认为的更类似于体内肿瘤的多步骤发展,不仅涉及活性癌基因的表达,还涉及抑制因子活性的丧失,这可能是由致染色体断裂的癌基因诱导的。